Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReGenHeart VEGF-D Gene Therapy in Refractory Angina
2024-512255-20-00Phase 2Completed
- Sponsor
- Pohjois-Savon hyvinvointialue
- Start
- May 2024
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in angina pectoris and coronary arteriosclerosis comparing AdsVEGF-D Delta N Delta C with Placebo (2 arms). Primary endpoints: Improvement of functional capacity using 6-minute walking test and Improvement of symptoms assessed by Canadian Cardiovascular Society (CCS) class. Started May 2024; status: completed.
02
Drugs
AdvVEGF-D
03
Conditions
angina pectoriscoronary arteriosclerosis
Beyond the preview
Go deeper on 2024-512255-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512255-20-00.